Enzo Biochem (NYSE:ENZ) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Enzo Biochem (NYSE:ENZ) from a hold rating to a buy rating in a report published on Saturday morning, ValuEngine reports.

Separately, TheStreet cut Enzo Biochem from a c- rating to a d+ rating in a report on Tuesday, November 12th.

ENZ stock opened at $2.73 on Friday. The company has a quick ratio of 4.60, a current ratio of 5.09 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average price is $2.98 and its 200-day moving average price is $3.41. Enzo Biochem has a one year low of $2.32 and a one year high of $4.46.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Tuesday, October 15th. The medical research company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $20.92 million during the quarter. Enzo Biochem had a negative return on equity of 33.03% and a net margin of 3.07%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Enzo Biochem during the second quarter valued at about $26,000. Tower Research Capital LLC TRC lifted its holdings in shares of Enzo Biochem by 558.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 14,820 shares of the medical research company’s stock worth $50,000 after acquiring an additional 12,570 shares during the last quarter. KBC Group NV lifted its holdings in shares of Enzo Biochem by 128.8% in the 2nd quarter. KBC Group NV now owns 17,048 shares of the medical research company’s stock worth $57,000 after acquiring an additional 9,598 shares during the last quarter. Cutter & CO Brokerage Inc. purchased a new position in shares of Enzo Biochem during the 2nd quarter worth approximately $63,000. Finally, Marshall Wace LLP purchased a new position in shares of Enzo Biochem during the 2nd quarter worth approximately $83,000. 68.70% of the stock is currently owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Recommended Story: The Structure of a Futures Contract

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.